Etonogestrel
- Generic Name
- Etonogestrel
- Brand Names
- Eluryng, Enilloring, Implanon, Nexplanon, Nuvaring
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28O2
- CAS Number
- 54048-10-1
- Unique Ingredient Identifier
- 304GTH6RNH
- Background
Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.
- Indication
Etonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.
Etonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.
- Associated Therapies
- Contraception, Contraceptive implant therapy
A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 210
- Registration Number
- NCT00725413
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 16
- Registration Number
- NCT00651807
A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)
- Conditions
- Contraception
- Interventions
- Drug: Radiopaque Implanon
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 108
- Registration Number
- NCT00620464
A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 301
- Registration Number
- NCT00620035
Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)
- Conditions
- Contraception
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 350
- Registration Number
- NCT00403793
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- HIV Infections
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: atazanavir/ritonavir dosage #1Drug: tipranavir/ritonavirDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #3Drug: levoflaxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.